About Cernostics

Cernostics is a life science company developing new molecular diagnostic tests for the fight against cancer. Most current diagnostic approaches offer a limited view of cancer because they fail to evaluate the tumor as a system composed of multiple cell types, not merely tumor cells.

Tumor as a system: Tumors are composed of many cell types, including tumor cells, immune cells such as macrophages, stromal cells such as fibroblasts and endothelial cells, and cancer stem cells. Anatomic pathology, the discipline of viewing tumor tissues on a glass slide, is the technique used for most cancer diagnoses and is, unfortunately limited in its ability to evaluate multiple biomarkers in this system.

Cernostics' technology and intellectual property is based on a systems approach to evaluating tissues via anatomic pathology, and simultaneously evaluates immune, stromal, stem cell and tumor biomarkers on a single slide while also preserving tissue structure.

In 2010, Cernostics, Inc. partnered with Geisinger Health System, recognized for its advanced use of the electronic health record, and the development and implementation of innovative care models. The system serves more than 2.6 million residents throughout 42 counties in central and northeastern Pennsylvania. For more information about Geisinger, visit www.geisinger.org. With offices in Pittsburgh and Danville, PA, Cernostics, Inc. is using "TissueCipher Pathology (TCP™)," a multiplexed fluorescence microscopy and digital imaging technology, to detect differences in the makeup of patient tissue samples and produce advanced cancer diagnostic products.